PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Location
23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA
Fiscal year end
April 30
Latest financial report
10-Q - Q2 2025 - Sep 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 802 % +1.56%
Debt-to-equity 11.2 % -80.2%
Return On Equity -2.51 % -103%
Return On Assets -2.26 % -106%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.8M shares -11.5%
Common Stock, Shares, Outstanding 6.8M shares -11.9%
Entity Public Float 12.5M USD -31.2%
Common Stock, Value, Issued 2.17K USD 0%
Weighted Average Number of Shares Outstanding, Basic 6.8M shares -13.6%
Weighted Average Number of Shares Outstanding, Diluted 6.8M shares -13.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 438K USD +9.67%
General and Administrative Expense 3.52M USD -40.6%
Operating Income (Loss) -3.96M USD +48.7%
Nonoperating Income (Expense) 2.83M USD -91.8%
Net Income (Loss) Attributable to Parent -1.13M USD -104%
Earnings Per Share, Basic 0 USD/shares -90.6%
Earnings Per Share, Diluted 0 USD/shares -90.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.2M USD -59.6%
Marketable Securities, Current 262K USD
Assets, Current 19.1M USD -41.9%
Intangible Assets, Net (Excluding Goodwill) 1.55M USD 0%
Assets 45.1M USD -35.7%
Accounts Payable, Current 465K USD -16%
Employee-related Liabilities, Current 135K USD -9.39%
Accrued Liabilities, Current 596K USD -12.9%
Liabilities, Current 1.06M USD -85.8%
Liabilities 1.52M USD -91.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -23.7K USD -1.79%
Retained Earnings (Accumulated Deficit) -93.3M USD -1.22%
Stockholders' Equity Attributable to Parent 43.6M USD -8.63%
Liabilities and Equity 45.1M USD -35.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.99M USD -434%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 21.7M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.99M USD +88.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.2M USD -59.6%
Deferred Tax Assets, Valuation Allowance 15.2M USD +0.18%
Deferred Tax Assets, Gross 16.9M USD +4.18%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.13M USD -104%
Deferred Tax Assets, Operating Loss Carryforwards 15M USD +4.07%
Preferred Stock, Shares Issued 35K shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 182M USD -0.64%
Preferred Stock, Shares Outstanding 35K shares
Deferred Tax Assets, Net of Valuation Allowance 15.2M USD +0.18%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%